Adjacent Evidence Brief: Telomere Cancer Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Surface every admitted source in the Evidence Landscape: each of the 26 admitted sources must appear in at least one outcome-class packet, with a one-sentence source-level finding and the direction coded consistently with the source's primary claim (not a single cherry-picked p-value).
2. Redesign the outcome-class taxonomy to separate mechanistic/preclinical (Afolabi, Alqaisi, Brown, Genetta, Aierken, Cheng, Xu, Gui, Bhat), prognostic-biomarker cohorts (Langsenlehner, Gil-Korilis, Ha, Sasmita, Sarkar), Mendelian randomization (Wan, Song, Markozannes, Chen), supplement/intervention trials (Jaeger, Brouwers), and contextual adjacent (Li, Davidson-Swinton, Liang, Liu, Andreikos, Alhareeri). Do not pool these under one header.
3. Recode direction values consistently: code 'unclear' only when the source genuinely does not report a directional effect; for sources that explicitly report longer-TL–increased-risk or shorter-TL–worse-survival, code direction accordingly (e.g., Davidson-Swinton, Chen, Wan, Andreikos, Song all report clear directional associations).
4. Replace the 'representative statistic' column with the source's primary effect estimate (HR, OR, beta, or risk difference) and its 95% CI where available; if a single number is shown, it must be the one the source itself foregrounds in its abstract or results.
5. Rewrite Key Findings as 4–6 concrete bullet findings (e.g., 'Longer genetically predicted LTL is associated with increased risk of lymphoid malignancy, glioma, melanoma, and prostate cancer across 4 MR studies; shorter LTL is associated with shorter OS/DFS in stage II/III CRC; one small RCT (n=40) reports TL lengthening with an Astragalus supplement at 6 months with no adverse events, but no cancer endpoint was assessed') so the synthesis delivers usable signal.
6. In the Conclusion, state explicitly what the corpus does and does not support: e.g., 'Evidence supports LTL as a prognostic biomarker in selected solid tumors; no direct interventional evidence supports a telomere-modifying intervention altering cancer incidence or mortality in humans.'
7. Tighten Gaps Identified to 3–5 specific, actionable gaps (e.g., 'No RCT of a telomere-modifying agent powered for cancer incidence or survival; no prespecified cancer endpoint in supplement/behavioral TL trials; prognostic signature studies (TCGA-derived) lack external prospective validation for TL-related gene panels').

Major issues

• The Evidence Landscape only reports 7 sources by name (Alhareeri, Jaeger, Li, Davidson-Swinton, Sasmita, Ha, Sarkar, Brouwers, Markozannes, Liang, Liu, Afolabi) but claims n=26 admitted sources. The remaining ~14 admitted sources (e.g., Langsenlehner, Gil-Korilis, Cheng, Bhat, Brown, Chen, Alqaisi, Genetta, Wan, Andreikos, Song, Aierken, Gui, Xu) appear in the bundle but are not surfaced in any outcome packet or the Evidence Landscape table, so the synthesis silently drops most of its corpus.
• Outcome-class table is internally inconsistent: the Contextual Adjacent Evidence row reports n=18 sources but only 4 source-level findings are listed; Mortality/Survival reports n=3 but only 3 are listed (mostly consistent); Longevity and Frailty report n=1 with a representative statistic that does not match a positive or negative direction in the listed source (e.g., Brouwers 2016 lists direction=positive despite p=0.88 and the source itself describing comparable LTL decline; Liang 2024 direction=unclear but the exemplar statistic p=0.3 is uninformative).
• The 'Contextual Adjacent Evidence' category is over-broad: it pools mechanistic reviews (Alqaisi, Chen, Andreikos, Afolabi), prognostic signature papers (Aierken, Cheng, Xu, Gui), Mendelian randomization studies (Wan, Song, Markozannes), radiation cohort studies (Langsenlehner), and supplement RCTs (Jaeger) under one undifferentiated header. This violates the stated evidence-tension synthesis principle of separating outcome classes and prevents audit of which signals come from which design.
• Direction coding is mostly 'unclear' across the corpus, so the 'significant statistic in 15/18 sources' and 'negative in 1/1' descriptors carry almost no informational content — they cannot be matched to a positive or negative effect on patient-relevant outcomes, undermining the value of the headline statistics.
• Several 'representative statistics' appear cherry-picked and decoupled from the primary finding of the source (e.g., Jaeger 2024 cites p=0.01 for TL lengthening but the source also reports no adverse events at 6 months in n=40, while Li 2026 cites p<0.05 for an LE8×PhenoAge interaction on lung cancer — neither statistic maps cleanly onto 'telomere cancer effects' as a primary endpoint).

Minor issues

• Search summary lists 12 information sources but provides no query-result counts per source, so the funnel cannot be audited at the source-database level.
• The 'Key Findings' section contains no actual key findings — only a repetition of the outcome-class disclaimer; this is a structural gap.
• The Article type is 'rapid_evidence_synthesis' but the manuscript reads as a corpus audit/adjacent-evidence brief; the distinction should be made explicit.
• Several sources in the bundle are dated 2026 (e.g., Li 2026, Davidson-Swinton 2026, Liu 2026, Sarkar 2026) — these appear to be in-press/early-view items; the manuscript should flag the year-future caveat.
• The Conclusion repeats the tiered-reading disclaimer four times without advancing the synthesis; consider trimming to one consolidated caveat.
• Gaps Identified says 'current direct evidence is 0/26 admitted source(s)' but also says '0/26' while also noting mortality/survival, dosing/PK, and contextual evidence — reconcile this with the per-class directness columns, which classify some as 'indirect' rather than 'direct.'

Reviewer note

The manuscript is a rapid evidence synthesis on telomere–cancer effects built from a 26-source bundle, and it correctly self-bounds by flagging that no direct interventional hard-endpoint evidence is retained. The search summary is unusually explicit (queries, eligibility, funnel, RoB framework, AI-use disclosure), and the source bundle is largely verifiable against DOIs and abstracts. The Conclusion appropriately resists clinical/policy escalation. However, the Evidence Landscape only surfaces ~12 of the 26 admitted sources by name; the rest of the corpus is invisible in the synthesis. The 'Contextual Adjacent Evidence' category pools mechanistically heterogeneous sources (MR, prognostic signatures, mechanistic reviews, supplement RCTs) under a single header, which contradicts the stated evidence-tension approach and prevents readers from seeing which signals come from which design. Direction coding is 'unclear' across most rows, so the headline statistics ('significant in 15/18') carry little informational content. Representative statistics appear cherry-picked (e.g., p=0.3 for Liang 2024, p=0.88 for Brouwers 2016 coded as 'positive'). These are bounded, fixable defects rather than a broken manuscript — the protocol and bundle are sound, but the synthesis layer needs to be rewritten to actually integrate the full corpus with consistent direction coding and design-stratified outcome classes. Revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis